A federal judge this week denied AstraZeneca’s request for a preliminary injunction against Mississippi’s contract pharmacy access law, marking the [...] …
Blog Posts
Federal lawmakers late last week approved a pared-down, must-pass federal spending bill, which cut back on health center funding and [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Senate Health, Education, Labor and Pensions (HELP) Committee—an influential panel with jurisdiction over the 340B program—will not only see [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
You’ve assessed your 340B program, identified compliance concerns, and incorporated necessary corrective actions into your 340B program operations. Now, you can sit back and wait until it’s time for your official HRSA
…
Biogen will soon extend its contract pharmacy restrictions to non-hospital covered entities, while Novartis will require hospitals to submit claims [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Michigan’s legislative session concluded in disarray last week after the House abruptly adjourned without enough members present to vote on [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A federal judge’s recent ruling against West Virginia’s 340B contract pharmacy law advances the drug industry’s push to bring the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Washington state could see greater cost reductions under a Medicaid fee-for-service pharmacy reimbursement model for 340B providers than through Medicaid [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Contract pharmacy restrictions—and legislation to override them—dominated 340B policy discussions in statehouses and courtrooms across the country this year, as [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
From drugmakers proposing new controversial 340B rebate models to federal lawmakers unveiling their first draft of a bipartisan-backed proposal to [...] …
